Besides triple-negative breast cancer, CMPBMC-Dor was also generated using the blood sample from a patient with ER+PR+HER2-, and we observed that it reduced fragment sizes of the cancer tissue from the same patient (Supplementary Fig. 5). This evidence concerns the gene ERBB2 and cancer.